先声药业 港股通 空最新回购 (2026-10-13) 官网 ( 02096.hk) | 15.79 | 2.60 | 1.87% (1.84%) | 上市时间2020-10-27股价11.020港币涨跌幅1.75%成交金额6,399.47万港币换手率0.23%总市值283.02亿港币H股市值283.02亿港币总股本25.68亿H股本25.68亿每手股数1,000 港股通持仓占H股比例11.99% (33.50亿港币2026-10-14) 累计做空占H股比例0.94% (2.63亿港币2026-10-09) 上市至今年化投资收益率2.06% | |||
| 所属三级行业药品 (恒生) | 市盈率 | 24.14 | 市净率 | 2.18 | 股息率 | 1.68% (1.58%) | 恒生:医疗保健业药品及生物科技药品 |
| 所属指数指数纳入纳出 | |||||||
| 备注 (8): | 双击编辑备注 |
先声药业(02096) - 历史董事名单
| # | 姓名 | 职衔 | 职位 | 委任日期 | 辞任日期 |
|---|---|---|---|---|---|
| 1 | 宋嘉桓 | Independent Non Executive Director | 2023-01-18 | -- | |
| 2 | 王熙 | Executive Director | 2023-01-18 | -- | |
| 3 | 宋瑞霖 | Independent Non Executive Director | 2019-11-19 | -- | |
| 4 | 唐任宏 | Executive Director | 2019-11-19 | -- | |
| 5 | 萬玉山 | Executive Director | 2019-11-19 | -- | |
| 6 | 汪建國 | Independent Non Executive Director | 2019-11-19 | -- | |
| 7 | 王新華 | Independent Non Executive Director - A/F | 2019-11-19 | -- | |
| 8 | 趙令歡 | Non Executive Director | 2019-11-19 | 2022-08-31 | |
| 9 | 張誠 | Executive Director | 2019-11-19 | 2021-03-31 | |
| 10 | 任晉生 | Executive Director | Chairman, CEO | 2015-11-30 | -- |